|
|
|
|
Crohn's Disease Medical and Health News Headlines
|
|
|
|
|
|
|
All Recent Crohn's Disease Medical Condition News Headlines |
|
|
|
|
Risk of tuberculosis from arthritis medication examined
(Wiley-Blackwell) Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. (Source: EurekAlert! - Medicine and Health)...
POSTED 06/29/2009 at 11:00 PM --
|
NOD2/CARD15 genotype and common gastrointestinal diseases in 43 600 individuals
Conclusions. NOD2/CARD15 polymorphisms are not major risk factors for common gastrointestinal diseases; however, we cannot completely exclude association with appendicitis, anal fissure, fistula and abscess, and gastrointestinal cancer. (Source: Journal of Internal Medicine)...
POSTED 06/29/2009 at 06:00 PM --
|
[The effectivity and safety of the biological therapy with adalimumab.]
Authors: Fehér J, Lengyel G
The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.
PMID:......
POSTED 06/27/2009 at 01:14 PM --
|
Novel polymeric film coatings for colon targeting: Drug release from coated pellets.
Authors: Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Flament MP, Dubreuil L, Desreumaux P, Siepmann J
The aim of this study was to prepare and characterize novel types of polymer coated pellets allowing for the site-specific delivery of drugs to the colon. 5-Aminosalicylic acid (5-ASA)-loaded beads were prepared by extrusion-spheronization and coated with different Nutriose:ethylcellulose blends. In vitro drug release from these systems was measured under various conditions, including the exposure to fresh fecal samples from inflammatory bowel disease patients under anaerobic conditions. Nutriose is a starch derivative, which is preferentially degraded by enzymes secreted by the microflora in the colon of Crohn's disease and ulcerative colitis patients. Interestingly, the releas......
POSTED 06/27/2009 at 10:56 AM --
|
Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease.
Authors: Andoh A, Benno Y, Kanauchi O, Fujiyama Y
Inflammatory bowel diseases [IBD], ulcerative colitis [UC] and Crohn's disease [CD], are chronic intestinal disorders of unknown etiology. UC and CD are heterogeneous diseases characterized by various genetic abnormalities that lead to overly aggressive T-cell responses to a subset of commensal enteric bacteria in genetically susceptible individuals. As one of critical factors involved in pathogenesis of IBD, relative imbalance of aggressive and protective bacterial species, termed dysbiosis, has been reported by various literatures. Since early days of microbiology, representatives of microbial species [over 400 species] have been isolated from human gastrointestinal tract, and analyses of dysbiosis in IBD were mainly dependent on cult......
POSTED 06/27/2009 at 10:42 AM --
|
The gut microbiota in inflammatory bowel disease.
Authors: Macfarlane GT, Blackett KL, Nakayama T, Steed H, Macfarlane S
Crohn's disease and ulcerative colitis are the two principal forms of inflammatory bowel disease (IBD). The root causes of these chronic and acute immunological disorders are unclear, but intestinal microorganisms are known to play a key role in the initiation and maintenance of disease. However, at present, there is no clear evidence for a single transmissible agent being involved in IBD aetiology. Although marked alterations occur in faecal and mucosal bacterial communities in IBD, it is unclear whether they are responsible for causing disease, or are due to changes in the gut environment that result from inflammatory reactions and extensive tissue destruction. Despite the involvement of microorganisms in inflamma......
POSTED 06/27/2009 at 10:42 AM --
|
Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans.
Authors: Lomax AR, Calder PC
A number of studies have been performed examining the influence of various probiotic organisms, either alone or in combination, on immune parameters, infectious outcomes, and inflammatory conditions in humans. Some components of the immune response, including phagocytosis, natural killer cell activity and mucosal immunoglobulin A production (especially in children), can be improved by some probiotic bacteria. Other components, including lymphocyte proliferation, the production of cytokines and of antibodies other than immunoglobulin A appear less sensitive to probiotics. Probiotics, including lactobacilli and bifidobacteria, administered to children can reduce incidence and duration of diarrhoea, but the precise effects depend upon the nature of the conditi......
POSTED 06/27/2009 at 10:42 AM --
|
Review article: diet and inflammatory bowel disease – epidemiology and treatment
Conclusions The current levels of knowledge concerning dietary risk factors for IBD, and the therapeutic efficacy of dietary and nutritional interventions need to be supported by well-designed trials in large cohorts of patients. (Source: Alimentary Pharmacology and Therapeutics)...
POSTED 06/26/2009 at 09:17 AM --
|
Takayasu's aortitis and infliximab
To The Editor: Filocamo et al reported the use of infliximab as adjunctive therapy for treating Takayasu's disease. Recently, we treated a 15-year-old girl who presented with weight loss, abdominal pain, and severe oral and perianal manifestations. The results of initial blood investigations showed high levels of inflammatory markers with a low albumin level. The diagnosis of perianal and ileo-colonic Crohn's disease was confirmed with endoscopy, ileo-colonoscopy, and biopsies. The presence of 1 perianal fistula was confirmed with magnetic resonance imaging. The patient failed to comply with nutritional therapy, and so she was given steroids and azathioprine. However, a few months later, she relapsed, and, after discussion with her and her family, infliximab (5 mg/kg) was started. She did......
POSTED 06/25/2009 at 09:25 AM --
|
Compugen Announces Positive Therapeutic Effects Of Novel Peptide In Animal Model Of Inflammatory Bowel Disease
Compugen Ltd. (NASDAQ:CGEN) announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease (IBD), a commonly used term covering ulcerative colitis and Crohn's disease. (Source: Health News from Medical News Today)...
POSTED 06/25/2009 at 06:00 AM --
|
Natalizumab gets an encore in Crohn's disease
(Source: PharmacoEconomics and Outcomes News)...
POSTED 06/25/2009 at 03:40 AM --
|
Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil
CONCLUSION: The inflammatory bowel diseases incidence in the studied area was as low as in other countries of Latin America and smaller than that found in countries of South Europe. The crescent prevalence justifies the policies to adequate medical cares for inflammatory bowel diseases patients in this area.CONTEXTO: No Brasil, a incidência e prevalência populacionais das doenças inflamatórias intestinais são desconhecidas. OBJETIVO: Neste trabalho, estimou-se esses parâmetros na área que abrange a antiga região de saúde DIR 11, no centro-oeste do Estado de São Paulo. MÉTODOS: Usou-se um registro sequencial de 115 pacientes (>15 anos de idade) com doenças inflamatórias intestinais, residindo na área de estudo, atendidos durante período de 20 anos (1986-2005) em hospital de r......
POSTED 06/25/2009 at 02:40 AM --
|
European evidence-based consensus on the management of ulcerative colitis - special situations
Published February 2008.Aims: This document sets out the current European Consensus on the diagnosis and management of UC, reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Berlin on 20th October 2006. ECCO is a forum for specialists in inflammatory bowel disease from 23 European countries. Like the initial Consensus on the management of Crohn's disease, the current Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This third section is on special situations including pouch disorders, cancer surveillance, pregnancy, paediatrics, psychosomatics, extra-intestinal manifestations and alternative therapy. (Source: Gastroenterology and Liver Diseases Specialist Library - Prevention)...
POSTED 06/22/2009 at 10:08 AM --
|
European evidence-based consensus on the management of ulcerative colitis - current management
Published February 2008.Aims: This document sets out the current European Consensus on the diagnosis and management of UC, reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Berlin on 20th October 2006. ECCO is a forum for specialists in inflammatory bowel disease from 23 European countries. Like the initial Consensus on the management of Crohn's disease, the current Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This second section is on current management, including treatment of active disease, maintenance of medically-induced remission and surgery of UC. (Source: Gastroenterology and Liver Diseases Specialist Library - Inflammatory bowel disease)...
POSTED 06/22/2009 at 10:03 AM --
|
European evidence-based consensus on the diagnosis and management of ulcerative colitis - definitions and diagnosis
Published in February 2008Aims: This document sets out the current European Consensus on the diagnosis and management of UC, reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Berlin on 20th October 2006. ECCO is a forum for specialists in inflammatory bowel disease from 23 European countries. Like the initial Consensus on the management of Crohn's disease, the current Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This first section concerns aims, methods and definitions of the Consensus, as well as classification, diagnosis, imaging and pathology of UC. (Source: Gastroenterology and Liver Diseases Specialist Library - Diagnostic procedures)...
POSTED 06/22/2009 at 10:00 AM --
|
Canadian Association of Gastroenterology clinical practice guidelines - the use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease
Published March 2009Aims: Guidelines regarding the use of infliximab in Crohn's disease were previously published by the CAG/ACG in 2004. Recent clinical findings and drug developments warrant a review and update of these guidelines. This document aims to review and update Canadian guidelines regarding the use of tumour necrosis factor-alpha antibody therapy in both luminal and fistulizing Crohn's disease. (Source: Gastroenterology and Liver Diseases Specialist Library - Inflammatory bowel disease)...
POSTED 06/22/2009 at 09:48 AM --
|
Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases
Inflammatory bowel disease (IBD) comprises two chronic, tissue-destructive, clinical entities: Crohn's disease (CD) and ulcerative colitis (UC), both immunologically based. Bowel symptoms are predominant, but extra-intestinal complications may occur, including involvement of the oral cavity. Oral involvement during IBD includes several types of lesions: the most common are aphthae; uncommon lesions include, among others, pyostomatitis vegetans and granulomatous lesions of CD. Starting with a presentation of six patients with oral manifestations, which were crucial for the final diagnosis of IBD, a review on the subject is presented. Oral involvement in IBD may be previous or simultaneous to the gastrointestinal symptoms. However, in the majority of cases, bowel disease precedes the onset o......
POSTED 06/21/2009 at 06:00 PM --
|
Hepatocellular carcinoma occurring in a young Crohn's disease patient
Reported herein is a case of hepatocellular carcinoma (HCC) occurring in a 25-year-old Japanese man who was diagnosed with Crohn's disease (CD) at 14 years of age; treatment included predonisolone, azathioprine, and infliximab. The tumor was located in right upper lobe and the size was 8 cm in diameter; histology was poorly differentiated HCC with pleomorphic cellular changes. Adjacent normal liver showed no evidence of cirrhosis or viral hepatitis. Until now, only six cases of HCC arising in patients with CD have been reported in the English-language literature. Most of these patients had early onset of CD and HCC: none had cirrhosis or virus hepatitis. Most patients had a long disease history of CD and were being medicated with several immunosuppressive agents. Some factors associated wi......
POSTED 06/21/2009 at 06:00 PM --
|
Comparison of the clinical features of recurrent aphthous stomatitis and Behçet's disease
Conclusion. These findings may provide guidelines for the clinical differentiation between RAS and BD. In addition, patients with multiple major aphthae, particularly with articular symptoms, should be closely followed up for the development of BD, and the possibility of other diseases such as ankylosing spondylitis and Crohn's disease should also be considered. (Source: Clinical And Experimental Dermatology)...
POSTED 06/21/2009 at 06:00 PM --
|
Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease
Conclusions Mutations in APC gene may occur in the non-dysplastic CD mucosa of patients with disease for more than 10 years. The follow-up of these patients
will show the likelihood of mutant APC progressing to CRC in CD. Further analysis will be required for evaluating the impact
of these findings in the context of cancer surveillance in inflammatory bowel disease.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00384-009-0748-5Authors
Davy Carlos Mendes Rapozo, Universidade do Estado do Rio de Janeiro Departamento de Bioquímica, Instituto de Biologia Rio de Janeiro Rio de Janeiro Brazil 20551030Ana Braunstein Grinmann, Universidade do Estado do Rio de Janeiro Disciplina de Gastroenterologia, Departamento de Medicina Interna, Faculdade de Ciê......
POSTED 06/20/2009 at 01:00 AM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
